Analyses at 62 months, or more than two years after treatment completion, confirm and extend the durable clinical and anticancer benefits of the bisphosphonate zoledronic acid that were reported at the 48-month follow-up in the Austrian Breast and Colorectal Cancer Study Group Trial 12...
Zoledronic acid improves survival in multiple myeloma patients versus the UK and European standard treatment of clodronic acid (sodium clodronate) in patients with multiple myeloma. Since overall survival in patients given zoledronic acid improved independently of prevention of skeletal-related...